Biolife4D Corp. on Monday said it was raising the size of its planned initial public offering to 3.6 million units from 2.4 million.
The units are still expected to price between $5.20 and $7.20 each, as previously disclosed, the company said.
The biotech company said it plans to “create a patient-specific, fully functioning heart through 3D bioprinting using the patient’s own cells.”
The company said it has applied to list on the Nasdaq Capital Market.
Aegis Capital Corp. is listed as the offering’s underwriter.